How Many 0.6 mg Doses in a Saxenda Pen?

How many 0.6 mg doses are in a Saxenda pen is a practical question for anyone starting liraglutide treatment. Each Saxenda pre-filled pen contains 3 mL of solution at a concentration of 6 mg/mL, giving 18 mg of liraglutide in total. At the 0.6 mg starting dose, each injection uses 0.1 mL, meaning one pen can deliver approximately 29 to 30 doses. Understanding this helps you plan your supply across the full dose escalation schedule, from the initial 0.6 mg dose through to the 3.0 mg maintenance dose.

How many doses does a Saxenda pen contain at the 0.6 mg setting?

A Saxenda pen contains approximately 29 to 30 doses at the 0.6 mg setting, as the 3 mL cartridge delivers 0.1 mL per dose, with a small amount used during priming.

A single Saxenda (liraglutide 6 mg/mL) pre-filled pen contains 3 mL of solution, giving a total of 18 mg of liraglutide per pen, which means it holds approximately 30 doses at the 0.^[1][2]6 mg setting. Each 0.6 mg dose requires 0.1 mL of solution, so the full 3 mL cartridge can theoretically deliver 30 individual injections at that starting dose. In practice, a small amount of solution is used during the priming step before the first injection, so the usable number of doses may be marginally lower, typically around 29 to 30.

Saxenda is a dial-a-dose pen, meaning the same device is used throughout the escalation schedule by simply adjusting the dose dial. This is an important distinction from single-use devices: the pen is not discarded after one injection. Each pen is designed to be used across multiple injections until the cartridge is empty or the pen has been in use for 30 days, whichever comes first.

Understanding how many doses a pen contains at each dose level helps with planning your supply and avoiding running out mid-week. Because the dose increases over time, the number of injections you get from each pen will decrease as you move up the escalation schedule. The sections below explain how this works in practice across the full titration period.

The pen volume, concentration and in-use period are set out in the Saxenda Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL), both available on the Electronic Medicines Compendium (emc). Priming steps and device operation are described in the Saxenda Instructions for Use, also available on the emc.

How the Saxenda dose escalation schedule works in the UK

The UK Saxenda escalation schedule starts at 0.6 mg daily and increases by 0.6 mg each week until the 3.0 mg maintenance dose is reached from week five onwards.

The Saxenda dose escalation schedule in the UK starts at 0.6 mg once daily for the first week and increases by 0.6 mg each week until the full maintenance dose of 3.0 mg once daily is reached. This stepwise approach is set out in the Saxenda SmPC (section 4.2) and is designed to reduce the likelihood and severity of gastrointestinal side effects, particularly nausea and vomiting, which are among the most commonly reported adverse effects with liraglutide.

The standard escalation schedule is as follows:

• Week 1: 0.6 mg once daily

• Week 2: 1.2 mg once daily

• Week 3: 1.8 mg once daily

• Week 4: 2.4 mg once daily

• Week 5 onwards: 3.0 mg once daily (maintenance dose)

If a patient does not tolerate a dose increase, their prescriber may advise staying at the current dose for an additional week before attempting to escalate again. This flexibility is built into clinical guidance to support adherence. Patients should not adjust their dose without speaking to their prescriber or pharmacist first.

The SmPC requires that treatment response is evaluated after 12 weeks on the 3.0 mg maintenance dose. If a patient has not lost at least 5% of their initial body weight by that point, the prescriber should consider whether continuing treatment is appropriate, as continued benefit is unlikely. Patients should discuss their progress with their prescriber at this stage.

In the UK, Saxenda is licensed as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related comorbidity. Prescribers assess eligibility on an individual basis, and local Integrated Care Boards (ICBs) determine NHS commissioning decisions for weight management medicines. For further context on UK care pathways, see NICE guideline NG224 on obesity and weight management.^[7]

How long will one Saxenda pen last at each dose level?

One Saxenda pen lasts approximately 30 days at 0.6 mg, reducing to around 6 days at the 3.0 mg maintenance dose, as higher doses use more solution per injection.

The number of days one Saxenda pen lasts depends directly on the daily dose being used, because higher doses consume more solution per injection. At the 0.6 mg starting dose, one pen provides approximately 30 daily doses, lasting around 30 days. As the dose increases, the duration per pen shortens considerably.

Here is a practical guide to how long one pen lasts at each dose level:

• 0.6 mg daily: approximately 30 days per pen

• 1.2 mg daily: approximately 15 days per pen

• 1.8 mg daily: approximately 10 days per pen

• 2.4 mg daily: approximately 7 to 8 days per pen

• 3.0 mg daily (maintenance): approximately 6 days per pen

These figures are approximate and assume no solution is lost beyond the initial priming step. At the maintenance dose of 3.0 mg, patients will typically need around five pens per month. Planning ahead is important, particularly during the escalation phase when the dose, and therefore the rate of pen use, changes weekly.

Patients should be aware that the 30-day in-use limit applies regardless of how much solution remains in the pen. The Saxenda PIL states that the pen must be discarded 30 days after first use, even if it is not empty.^[1][2] This means that at lower doses, where a pen could theoretically last longer than 30 days, it must still be replaced at the 30-day mark to ensure product integrity and safety. Real-world pen duration may also be affected by priming and injection technique, as described in the Saxenda Instructions for Use.

What affects how many doses you get from a Saxenda pen?

Priming, incorrect injection technique, leaving a needle attached between doses, and the mandatory 30-day discard rule are the main factors that reduce usable doses from a Saxenda pen.

Several practical factors can reduce the number of usable doses from a Saxenda pen beyond the theoretical maximum. Understanding these helps patients manage their supply more effectively and avoid unexpected shortfalls.

Priming the pen is the most consistent factor. Before the first injection from a new pen, the device must be primed to remove air from the cartridge and confirm the pen is working correctly. This uses a small amount of solution and is a necessary step, not an optional one. Skipping priming risks an inaccurate dose. Full priming instructions are set out in the Saxenda Instructions for Use.

Incorrect dialling or injection technique can also result in wasted solution. If the dose dial is set incorrectly and then reset, or if the injection button is not held down for the full duration specified in the Instructions for Use after inserting the needle, some solution may not be delivered. Patients should follow the Instructions for Use carefully and ask their pharmacist to demonstrate the technique if they are unsure.

The 30-day in-use rule means that any solution remaining in the pen after 30 days must be discarded. At lower doses, this is the most significant limiting factor, as a pen used at 0.6 mg daily could theoretically last the full month but must still be replaced on schedule.

Needle attachment and removal should be done correctly each time. Leaving a needle attached between injections can allow air to enter the cartridge or solution to leak, both of which reduce the available dose. The PIL advises removing the needle after each injection and disposing of it safely in a sharps bin. Needles and pens must never be shared with another person. Contact your local council or pharmacy for information on obtaining a sharps bin if you do not already have one.

For patients accessing Saxenda through an online consultation, Bolt Pharmacy is a GPhC-registered online pharmacy in Great Britain offering weight-management consultations, with prescriber review and pharmacist support, alongside other treatment pathways a clinician may consider.

Storing your Saxenda pen correctly to avoid wasted doses

Unused Saxenda pens must be refrigerated at 2°C to 8°C; after first use, they can be kept below 30°C but must be discarded 30 days after opening regardless of remaining solution.

Saxenda pens must be stored correctly to preserve the integrity of the liraglutide solution and avoid wasting doses through degradation. The storage information below is drawn from the Saxenda PIL.

Before first use, Saxenda pens should be stored in a refrigerator at 2°C to 8°C and must not be frozen. Freezing the solution renders it unusable and the pen must be discarded if this occurs.

After the first use, the pen can be kept either in the refrigerator (2°C to 8°C) or at room temperature below 30°C. The pen must be discarded 30 days after first use regardless of storage conditions.^[1][2] It is good practice to note the date of first use on the pen label or in a diary to avoid uncertainty.

Additional storage points to be aware of include:

• Keep the pen cap on when not in use to protect the cartridge from light and contamination.

• Do not store the pen with a needle attached, as this can cause air bubbles to form in the cartridge and may lead to leakage.

• Keep the pen away from direct heat and sunlight, including car dashboards and windowsills, particularly during warmer months.

• Do not use a pen that has been frozen, dropped heavily, or that contains solution that appears cloudy, discoloured, or contains particles. Saxenda solution should be clear and colourless.

Patients travelling should plan storage carefully, particularly on long-haul flights or in hot climates. Insulated cool bags designed for insulin pens are suitable for transporting Saxenda. If there is any doubt about whether a pen has been stored correctly, patients should contact their pharmacist before using it rather than risk an ineffective or unsafe dose.

Side effects to watch for as you increase your Saxenda dose

Gastrointestinal effects such as nausea, vomiting, and diarrhoea are the most common side effects during Saxenda dose escalation; severe abdominal pain or persistent vomiting requires prompt medical attention.

Gastrointestinal side effects are the most commonly reported adverse effects with Saxenda, and they tend to be most noticeable during the dose escalation phase. Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort are all listed in the Saxenda SmPC (section 4.8) as very common or common adverse effects. These effects often improve as the body adjusts to each new dose level, which is one of the reasons the gradual escalation schedule is recommended.

Patients should be aware of the following side effects and when to seek advice:

• Nausea and vomiting: Usually mild to moderate and transient. Eating smaller meals and avoiding fatty or spicy foods can help. If vomiting is persistent or severe, or if you are unable to keep fluids down, contact your GP or call NHS 111. Persistent vomiting or diarrhoea can lead to dehydration; seek medical advice promptly if you notice reduced urine output or feel faint.

• Hypoglycaemia (low blood sugar): More likely in patients also taking insulin or a sulphonylurea.^[1][3] Symptoms include shakiness, sweating, confusion and palpitations. If you experience these, follow your hypoglycaemia management plan and contact your GP if episodes are frequent.

• Pancreatitis: The Saxenda SmPC notes that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis. Persistent, severe abdominal pain that may radiate to the back should be assessed urgently. Contact NHS 111 or attend A&E if the pain is severe and sudden.

• Gallbladder disease: GLP-1 receptor agonists and weight loss are both associated with an increased risk of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis).^[1][5] Seek urgent medical attention if you develop severe pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice), as these may indicate a gallbladder problem.

• Heart rate increase: Liraglutide can increase resting heart rate.^[1][6] Patients with pre-existing cardiac conditions should discuss this with their prescriber.

• Injection site reactions: Redness, bruising or discomfort at the injection site are common and usually resolve. Rotating injection sites helps reduce this.

• Pregnancy and breastfeeding: Saxenda must not be used during pregnancy or whilst breastfeeding. If you become pregnant, think you may be pregnant, or are planning a pregnancy, stop taking Saxenda and contact your prescriber promptly. Women of childbearing potential should discuss contraception with their prescriber before starting treatment, in line with the Saxenda SmPC (section 4.4).

Any suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you are concerned about a new or worsening symptom at any dose level, speak to your GP or pharmacist promptly.

Scientific References

1. Saxenda 6 mg/mL solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
2. Saxenda 6 mg/mL solution for injection in pre-filled pen – Patient Information Leaflet (PIL).
3. Saxenda (liraglutide) – EPAR Product Information.
4. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
5. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases.
6. Heart rate increases in liraglutide treated chronic heart failure patients.
7. Overweight and obesity management (NG246).
8. Liraglutide – British National Formulary (BNF).

Frequently Asked Questions